Blerp – Lifestyle
Author:
Spyre Therapeutics, Inc.
Spyre Therapeutics Announces Grants of Inducement Awards
May 1, 2026
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
April 16, 2026
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
April 14, 2026
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
April 13, 2026
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
April 13, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
April 3, 2026
Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026
March 16, 2026
Spyre Therapeutics Announces Grants of Inducement Awards
March 6, 2026